Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Very Bullish +80

Cigna Earnings Call Highlights Growth, EPS Upgrade

📈 Cigna reported Q1 2026 revenue of $68.5 billion and adjusted EPS of $7.79, reflecting a 16% year-over-year earnings increase.

💰 The company raised its full-year 2026 adjusted EPS guidance to at least $30.35 based on strong portfolio performance.

🏥 Evernorth segment revenue grew 9% to $58.4 billion with pretax adjusted earnings reaching $1.5 billion.

🔬 Specialty and Care Services posted 20% year-over-year pretax adjusted earnings growth driven by high-margin clinical offerings.

💊 Cigna Healthcare generated $1.5 billion in pretax adjusted earnings on $11.5 billion revenue with an MCR of 79.8%.

📱 Administrative friction decreased significantly as the company removed hundreds of tests and procedures from prior authorization requirements.

🏆 Cigna Healthcare ranked first in J.D. Power’s digital experience satisfaction for commercial members for the second consecutive year.

💡 A new rebate-free pharmacy service model called "Signature" offers brand drugs at approximately 30% lower prices with greater transparency.

🤖 AI tools and predictive models are driving operating efficiencies, reducing inbound calls by up to 25% in Pharmacy Benefit Services.

🏦 The company generated $1.1 billion in operating cash flow and improved its debt-to-capitalization ratio to 42.3%.

⚠️ Pharmacy Benefit Services pretax adjusted earnings fell 28% year-over-year due to large client renewals and upfront investments in the new Signature model.

📉 After-tax special items charges totaled $322 million or $1.22 per share in Q1, excluding them from adjusted EPS metrics.

✂️ Cigna plans to exit its individual exchange business by year-end 2026 and is reviewing its eviCore operation to sharpen strategic focus.

🤝 Noncontrolling interests rose to $226 million due to a new joint venture with a major client, adding complexity to earnings modeling.

🚀 Management emphasizes that near-term pressures from portfolio pruning are intentional steps to support long-term value creation.

Bullish Signals
  • Cigna reported Q1 2026 revenue of $68.5 billion and adjusted EPS of $7.79, representing 16% year-over-year earnings growth.
  • The company raised its full-year 2026 adjusted EPS guidance to at least $30.35, signaling strong confidence in future performance despite known headwinds.
  • Evernorth revenues climbed 9% year-over-year to $58.4 billion, supported by continued uptake of its health services platform.
  • Pretax adjusted earnings for Evernorth reached $1.5 billion, slightly ahead of expectations and demonstrating profitable growth during heavy investment periods.
  • Specialty and Care Services delivered 20% year-over-year pretax adjusted earnings growth to $1.1 billion, highlighting the strength of higher-margin clinical offerings.
  • Cigna Healthcare posted a medical care ratio of 79.8%, which is better than expectations and provides a cushion against seasonal normalization.
  • Cigna ranked first in J.D. Power's digital experience satisfaction for commercial members for a second consecutive year, underscoring strong member engagement.
  • The company unveiled its new "Signature" rebate-free pharmacy service model offering brand drugs at prices about 30% lower with greater transparency, receiving encouraging early feedback.
  • Digital and AI-enabled tools translated into tangible operating efficiencies, including a 20% reduction in inbound calls among U.S. employer customers and a 25% decline for Pharmacy Benefit Services members.
  • The company generated $1.1 billion of operating cash flow in Q1, reinforcing its ability to fund reinvestment and dividends while improving its debt-to-capitalization ratio by 70 basis points.
  • Cigna is guiding to further leverage reduction by year-end 2026 as part of its balanced capital allocation framework.
Risk Factors
  • Cigna reported Q1 2026 pretax adjusted earnings for Pharmacy Benefit Services fell 28% year-over-year to $394 million, representing roughly a $150 million quarterly decline driven by large client renewals and upfront investments in the new Signature model.
  • The company incurred after-tax special items charges of $322 million in Q1 2026, equivalent to $1.22 per share, which negatively impacted reported earnings despite management excluding them from adjusted metrics.
  • Cigna plans to exit the individual exchange business by year-end and has initiated a strategic review of its eviCore operation, actions that will trim near-term revenue while they transition focus.
  • Noncontrolling interest climbed to $226 million in the quarter, more than doubling from the prior year due to a new joint venture that adds modeling complexity and affects the split of earnings.
  • Management acknowledged rising pressure in Pharmacy Benefit Services and portfolio pruning as intentional steps that may detract from current performance while aiming for long-term value.
Full Analysis
Cigna Group (CI) reported strong first-quarter 2026 results, delivering consolidated revenue of $68.5 billion and adjusted EPS of $7.79, which reflects a 16% year-over-year increase. On the back of this performance, management raised its full-year 2026 adjusted EPS guidance to at least $30.35 per share. The company highlighted robust growth in its core healthcare business, while acknowledging temporary pressures within its Pharmacy Benefit Services segment driven by strategic transitions and large client renewals. Key financial highlights include Cigna Healthcare generating $1.5 billion in pretax adjusted earnings with a medical care ratio of 79.8%, exceeding expectations. The Specialty and Care Services division also delivered strong results with 20% year-over-year pretax adjusted earnings growth to $1.1 billion, fueled by volume increases and higher-margin clinical offerings. Meanwhile, Evernorth saw revenue climb 9% to $58.4 billion, though its Pharmacy Benefit Services segment recorded a decline in earnings due to upfront investments for new models and client extensions. Management emphasized operational efficiency gains through digital adoption and AI implementation, citing a 20% reduction in inbound calls for eligible U.S. employer customers and a 15% cut in prior authorization volume. Innovation efforts included launching a rebate-free "Signature" pharmacy model offering brand drugs at approximately 30% lower prices and deploying predictive models that save around $2,000 annually per engaged member. The company maintained capital discipline with $1.1 billion in operating cash flow and ended the quarter with a debt-to-capitalization ratio of 42.3%, down from 43%. Looking ahead, Cigna outlined strategic moves to sharpen focus, including plans to exit its individual exchange business by year-end 2026 and initiate a strategic review of its eviCore operation. While these steps involve near-term costs such as $322 million in after-tax special items charges, leadership views them as necessary for long-term value creation. Additionally, the company is managing rising noncontrolling interests stemming from new joint ventures, acknowledging the modeling complexity while noting that the financial impact has been incorporated into its forecasts.